| [1] |
Boussi LS， Avigan ZM， Rosenblatt J．Immunotherapy for the treatment of multiple myeloma[J]. Front Immunol， 2022 (13)：1027385.DOI： 10.3389/fimmu.2022.1027385.
|
| [2] |
Zhang L， Tai YT， Ho M，et al.Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu[J]. Blood Cancer J， 2017， 7(3)：e547.DOI： 10.1038/bcj.2017.24.
|
| [3] |
Bartosińska J， Purkot J， Karczmarczyk A，et al.Differential function of a novel population of the CD19 ＋CD24 hiCD38 hi Bregs in psoriasis and multiple myeloma[J]. Cells， 2021， 10(2)：411.DOI： 10.3390/cells10020411.
|
| [4] |
Tang W， Li Y， Zou Z，et al.A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma[J]. Cancer Med， 2023， 12(3)：3054-3067.DOI： 10.1002/cam4.5228.
|
| [5] |
|
| [6] |
Michaud D， Steward CR， Mirlekar B，et al.Regulatory B cells in cancer[J]. Immunol Rev， 2021， 299(1)：74-92.DOI： 10.1111/imr.12939.
|
| [7] |
Yanaba K， Bouaziz JD， Haas KM，et al.A regulatory B cell subset with a unique CD1dhiCD5＋ phenotype controls T cell-dependent inflammatory responses[J]. Immunity， 2008， 28(5)：639-650.DOI： 10.1016/j.immuni.2008.03.017.
|
| [8] |
Zhang Y, Li J, Zhou N, et al. The unknown aspect of BAFF：inducing IL-35 production by a CD5＋CD1dhiFcγRIIbhi regulatory B-cell subset in lupus[J]. J Invest Dermatol， 2017， 137(12)：2532-2543.DOI： 10.1016/j.jid.2017.07.843.
|
| [9] |
Lundy SK， Fox DA.Reduced Fas ligand-expressing splenic CD5 ＋ B lymphocytes in severe collagen-induced arthritis[J]. Arthritis Res Ther， 2009， 11(4)：R128.DOI： 10.1186/ar2795.
|
| [10] |
Shalapour S， Font-Burgada J， Di Caro G，et al.Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy[J]. Nature， 2015， 521(7550)：94-98.DOI： 10.1038/nature14395.
|
| [11] |
Xu L, Liu X, Liu H, et al. Impairment of granzyme B-producing regulatory B Cells correlates with exacerbated rheumatoid arthritis[J]. Front Immunol， 2017(8)：768.DOI： 10.3389/fimmu.2017.00768.
|
| [12] |
Meng L， Almeida LN， Clauder AK，et al.Bone marrow plasma cells modulate local myeloid-lineage differentiation via IL-10[J]. Front Immunol， 2019(10)：1183.DOI： 10.3389/fimmu.2019.01183.
|
| [13] |
|
| [14] |
|
| [15] |
Lino AC， Dang VD， Lampropoulou V，et al.LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells[J]. Immunity， 2018， 49(1)：120-133.e9.DOI： 10.1016/j.immuni.2018.06.007.
|
| [16] |
Catalán D, Mansilla MA, Ferrier A, et al. Immunosuppressive mechanisms of regulatory B Cells[J]. Front Immunol， 2021(12)：611795.DOI： 10.3389/fimmu.2021.611795.
|
| [17] |
Lee KM， Stott RT， Zhao G，et al.TGF-β-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance[J]. Eur J Immunol， 2014， 44(6)：1728-1736.DOI： 10.1002/eji.201344062.
|
| [18] |
Bodogai M， Moritoh K， Lee-Chang C，et al.Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associated B Cells[J]. Cancer Res， 2015， 75(17)：3456-3465.DOI： 10.1158/0008-5472.CAN-14-3077.
|
| [19] |
Dambuza IM， He C， Choi JK，et al.IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease[J]. Nat Commun， 2017， 8(1)：719.DOI： 10.1038/s41467-017-00838-4.
|
| [20] |
Abebe EC， Dejenie TA， Ayele TM，et al.The role of regulatory B cells in health and diseases：a systemic review[J]. J Inflamm Res， 2021(14)：75-84.DOI： 10.2147/JIR.S286426.
|
| [21] |
Oleinika K， Rosser EC， Matei DE，et al.CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells[J]. Nat Commun， 2018， 9(1)：684.DOI： 10.1038/s41467-018-02911-y.
|
| [22] |
Chen Y， Li C， Lu Y，et al.IL-10-producing CD1d hiCD5＋ regulatory B Cells may play a critical role in modulating immune homeostasis in silicosis patients[J]. Front Immunol， 2017(8)：110.DOI： 10.3389/fimmu.2017.00110.
|
| [23] |
Bosma A， Abdel-Gadir A， Isenberg DA，et al.Lipid-antigen presentation by CD1d(＋) B cells is essential for the maintenance of invariant natural killer T cells[J]. Immunity， 2012， 36(3)：477-490.DOI： 10.1016/j.immuni.2012.02.008.
|
| [24] |
Ding Q， Yeung M， Camirand G，et al.Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice[J]. J Clin Invest， 2011， 121(9)：3645-3656.DOI： 10.1172/JCI46274.
|
| [25] |
Cherukuri A， Mohib K， Rothstein DM.Regulatory B cells：TIM-1，transplant tolerance，and rejection[J]. Immunol Rev， 2021， 299(1)：31-44.DOI： 10.1111/imr.12933.
|
| [26] |
Aravena O, Ferrier A, Menon M, et al. TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients[J]. Arthritis Res Ther， 2017， 19(1)：8.DOI： 10.1186/s13075-016-1213-9.
|
| [27] |
Ma L， Liu B， Jiang Z，et al.Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis[J]. Clin Rheumatol， 2014， 33(2)：187-195.DOI： 10.1007/s10067-013-2359-3.
|
| [28] |
Xiao S, Bod L, Pochet N, et al. Checkpoint receptor TIGIT expressed on Tim-1 ＋ B Cells regulates tissue inflammation[J]. Cell Rep， 2020， 32(2)：107892.DOI： 10.1016/j.celrep.2020.107892.
|
| [29] |
Xiao X， Lao XM， Chen MM，et al.PD-1 hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression[J]. Cancer Discov， 2016， 6(5)：546-559.DOI： 10.1158/2159-8290.CD-15-1408.
|
| [30] |
Wang X， Wang G， Wang Z，et al.PD-1-expressing B cells suppress CD4＋ and CD8＋ T cells via PD-1/PD-L1-dependent pathway[J]. Mol Immunol， 2019(109)：20-26.DOI： 10.1016/j.molimm.2019.02.009.
|
| [31] |
Khan AR， Hams E， Floudas A，et al.PD-L1 hi B cells are critical regulators of humoral immunity[J]. Nat Commun， 2015(6)：5997.DOI： 10.1038/ncomms6997.
|
| [32] |
Jiao Y, Yi M, Xu L, et al. CD38：targeted therapy in multiple myeloma and therapeutic potential for solid cancers[J]. Expert Opin Investig Drugs， 2020， 29(11)：1295-1308.DOI： 10.1080/13543784.2020.1814253.
|
| [33] |
Swamydas M， Murphy EV， Ignatz-Hoover JJ，et al.Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma[J]. J Hematol Oncol， 2022， 15(1)：17.DOI： 10.1186/s13045-022-01234-2.
|
| [34] |
Uckun FM.Overcoming the immunosuppressive tumor microenvironment in multiple myeloma[J]. Cancers (Basel)， 2021， 13(9)：2018.DOI： 10.3390/cancers13092018.
|
| [35] |
Tai YT， Lin L， Xing L，et al.APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma：therapeutic implications[J]. Leukemia， 2019， 33(2)：426-438.DOI： 10.1038/s41375-018-0242-6.
|
| [36] |
Alexandrakis MG, Goulidaki N, Pappa CA, et al. Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma[J]. Pathol Oncol Res， 2015， 21(4)：929-934.DOI： 10.1007/s12253-015-9921-z.
|
| [37] |
Michaud D， Steward CR， Mirlekar B，et al.Regulatory B cells in cancer[J]. Immunol Rev， 2021， 299(1)：74-92.DOI： 10.1111/imr.12939.
|
| [38] |
Cui J， Zou Z， Duan J，et al.Predictive values of PET/CT in combination with regulatory B Cells for therapeutic response and survival in contemporary patients with newly diagnosed multiple myeloma[J]. Front Immunol， 2021(12)：671904.DOI： 10.3389/fimmu.2021.671904.
|
| [39] |
Prabhala R， Samur MK， Talluri S，et al.Favorable progression-free survival associated with immune bio-markers modulated by pomalidomide in relapsed/refractory multiple myeloma：an analysis of phase III study[J]. Blood， 2019， 134 (Supplement_1)：1784.DOI： 10.1182/blood-2019-131257.
|